Frequency and clinical features of the JAK2 V617F mutation in pediatric patients with sporadic essential thrombocythemia

Pediatric Blood and Cancer

Volumn 51, Issue 6, 2008, Pages 802-805

  Nakatani, Takuya ^a   Imamura, Toshihiko ^a   Ishida, Hiroyuki ^b   Wakaizumi, Katsuji ^c   Yamamoto, Tohru ^d   Otabe, Osamu ^e   Ishigami, Tsuyoshi ^f   Adachi, Souichi ^g   Morimoto, Akira ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b MATSUSHITA MEMORIAL HOSPITAL   (Japan)

^c Medical Care Center   (Japan)

^d NANTAN GENERAL HOSPITAL   (Japan)

^e Tanabe Chuo Hospital   (Japan)

^f Hikone Municipal Hospital   (Japan)

^g KYOTO UNIVERSITY   (Japan)

Author keywords

Essential thrombocythemia; JAK2 V617F mutation; Pediatric

Indexed keywords

BIOLOGICAL MARKER; JANUS KINASE 2; POLYCYTHEMIA RUBRA VERA 1 PROTEIN; UNCLASSIFIED DRUG;

ADOLESCENT; ALLELE; ARTICLE; CHILD; CLINICAL ARTICLE; EXON; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENE MUTATION; GENOTYPE; GRANULOCYTE; HEADACHE; HUMAN; INFANT; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; THROMBOTIC THROMBOCYTOPENIC PURPURA; WORLD HEALTH ORGANIZATION;

ADOLESCENT; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; EXONS; FEMALE; HUMANS; INFANT; ISOANTIGENS; JANUS KINASE 2; MALE; MEMBRANE GLYCOPROTEINS; MUTATION; NEUTROPHILS; POLYMERASE CHAIN REACTION; RECEPTORS, CELL SURFACE; THROMBOCYTHEMIA, ESSENTIAL;

EID: 56749154672     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21730     Document Type: Article

References (20)

1. El-Moneim AA, Kratz CP, Boll S, et al. Essential versus reactive thrombocythemia in children: Retrospective analyses of 10 cases. Pediatr Blood Cancer 2007;49:52-55.
2. Dame C, Sutor AH. Primary and secondary thrombocytosis in childhood. Br J Haematol 2005;109:165-177.
3. Hasle H. Incidence of essential thrombocythemia in children. Br J Haematol 2000;120:751.
4. Baxter EJ, Scott LM, Cambell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-1061.
5. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer cell 2005;7:387-397.
6. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-1790.
7. Randi ML, Putti MC, Scapin M, et al. Pediatric patients with essential thrombocythemia are mostly polyclonal and V617F JAK2 negative. Blood 2006;108:3600-3602.
8. Park MJ, Shimada A, Asada H, et al. JAK2 mutation in a boy with polycythemia vera, but not in other pediatric hematological disorders. Leukemia 2006;20:1453-1454.
9. Teofili L, Giona F, Martini M, et al. Markers of myeloproliferative disease in childhood polycythemia vera and essential thrombocythemia. J Clin Oncol 2007;25:1048-1053.
10. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292-2302.
11. Campbell P, Scott LM, Buck G, et al. Definition of subtypes of essential thrombocythemia and relation to polycythaemia vera based on JAK2 V617F mutation status: A prospective study. Lancet 2005;366:1945-1953.
12. Laurent C, Demas V, Delabesse E, et al. Detection of the MPL W515L mutation in bone marrow core biopsy specimens with essential thrombocythemia using the TaqMan assay. Hum Pathol 2007;38:1581-1582.
13. Linda MS, Ton W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007;356:459-468.
14. Teofili L, Martini M, Luongo M, et al. Overexpression of the polycythemia rubra vera-1 gene in essential thrombocythemia. J Clin Oncol 2002;20:4249-4254.
15. Kratz CP, Boll S, Kontny U, et al. Mutational screen reveals a novel JAK2 mutation, 1612s, in a child with acute lymphoblastic leukemia. Leukemia 2006;20:381-383.
16. Gale RE, Allen AJR, Nash MJ, et al. Long-term serial analysis of X-chromosome inactivation patterns and JAK2 V617F mutant levels in patients with essential thrombocythemia show that minor mutant-positive clones can remain stable for many years. Blood 2007;109:1241-1243.
17. Harrison CN, Green AR. Essential thrombocythemia. Hematol Oncol Clin North Am 2003;17:1275-1290.
18. Sitrin RG, Pan PM, Blackwood RA, et al. Cutting edge: Evidence for a signaling partnership between urokinase receptors (CD87) and L-selectin (CD62L) in human polymorphonuclear neutrophils. J Immunol 2001;166:4822-4825.
19. Animesh DP, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: A study of 1182 patients. Blood 2006;108:3472-3476.
20. Beer P, Cambell P, Erber W, et al. Clinical significance of MPL mutations in essential thrombocythemia: Analysis of the PT-1 cohort. Blood 2007;110:208a-209a.